U.S. health authorities have informed executives at Merck, Sanofi, and AstraZeneca that their infant RSV therapies will undergo renewed safety scrutiny. The decision comes amid heightened attention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback